- 同
- Survanta
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/07/07 15:01:54」(JST)
wiki en
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 早産児における呼吸窮迫症候群の予防および治療 prevention and treatment of respiratory distress syndrome in preterm infants
English Journal
- Improvement of pulmonary surfactant activity by introducing D-amino acids into highly hydrophobic amphiphilic α-peptide Hel 13-5.
- Nakamura Y1, Yukitake K2, Nakahara H3, Lee S4, Shibata O5, Lee S6.
- Biochimica et biophysica acta.Biochim Biophys Acta.2014 Aug;1838(8):2046-52. doi: 10.1016/j.bbamem.2014.04.024. Epub 2014 May 2.
- The high costs of artificial pulmonary surfactants, ranging in hundreds per kilogram of body weight, used for treating the respiratory distress syndrome (RDS) premature babies have limited their applications. We have extensively studied soy lecithins and higher alcohols as lipid alternatives to expe
- PMID 24796503
- Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome.
- Eras Z, Dizdar EA, Kanmaz G, Guzoglu N, Aksoy HT, Altunkaya GB, Canpolat FE, Dilmen U.
- American journal of perinatology.Am J Perinatol.2014 Jun;31(6):463-8. doi: 10.1055/s-0033-1351659. Epub 2013 Jul 24.
- BACKGROUND: Some controlled trials have shown significant differences in short-term clinical outcomes between poractant alfa and beractant in infants with respiratory distress syndrome (RDS). There is, however, no study showing the differences in long-term outcomes with these treatments.AIM: To dete
- PMID 23884719
- Perfusion Index Variability in Preterm Infants Treated with Two Different Natural Surfactants for Respiratory Distress Syndrome.
- Karadag N, Dilli D, Zenciroglu A, Aydin B, Beken S, Okumus N.
- American journal of perinatology.Am J Perinatol.2014 Feb 24. [Epub ahead of print]
- Objective The objective of this study was to compare the perfusion index (PI) variability in premature infants with respiratory distress syndrome (RDS) following administration of two different natural surfactant preparations. Study design This was a prospective study on 92 preterm infants with
- PMID 24566756
Japanese Journal
- Surfactant (Beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: Evidence of persistent surfactant deficiency.
- LOTZE A.
- J Pediatr Surg 29, 407-412, 1994
- NAID 10007082426
Related Links
- Learn about SURVANTA® (beractant) dosing, administration, safety and efficacy for prevention and treatment of respiratory distress syndrome (RDS) ... SAFETY CONSIDERATIONS 2 SURVANTA is intended for intratracheal use ...
- Beractant is a lung surface acting agent, or "surfactant." It helps the lungs function normally. Beractant is similar to the natural fluid in the lungs that helps maintain effective breathing. Beractant is used to treat or prevent respiratory ...
Related Pictures
★リンクテーブル★
| リンク元 | 「肺表面活性物質」 |
「肺表面活性物質」
- 胎児のII型肺胞上皮細胞で在胎20週ころから産生され始め、在胎32週以降に急激に産生が増加する (PED.396) → 胎児#胎児の成長
- 胎児の肺は妊娠26週には構造が完成し、妊娠34週頃には肺のサーファクタント産生が十分量に達して機能的に成熟(G10M.144)
- 肺サーファクタントが羊水に出現するのは妊娠28-32週ごろ (出典不明)
米国
- Surfaxin(lucinactant)
- Survanta(beractant)
- Curosurf(poractantalpha)
- Infasurf(calfactant)